According to the results that a patient’s therapeutic response is related to the expression of MMP-9 and TIMP-1, the authors speculate that it is possible to reduce the expression of MMP-9 and TIMP-1 through early active intervention, and alleviate the severity of ECM degradation, airway inflammation, fibrosis and airway remodeling slow the decline of FEV1 in COPD patients, and improve the quality of life. This evidence concerns the gene MMP9 and chronic obstructive pulmonary disease.